Osteopenia Treatment Guidelines

First-Line Medications

The American Academy of Family Physicians recommends bisphosphonates as the first-line pharmacological treatment for osteopenia, with oral alendronate being the most commonly recommended medication due to its established efficacy, safety profile, and cost-effectiveness 1, 2, 3
Oral alendronate is recommended at a prevention dose of 5 mg daily or 35 mg once weekly, and a treatment dose of 10 mg daily or 70 mg once weekly 1, 2
Risedronate is recommended at a dose of 5 mg daily, 35 mg weekly, 75 mg on two consecutive days monthly, or 150 mg monthly 1, 2, 3
Ibandronate is recommended at a dose of 150 mg monthly orally or 3 mg IV every three months 1, 2
Zoledronic acid is recommended at a dose of 5 mg IV every two years for prevention and 5 mg IV annually for treatment 1, 2

Raloxifene is recommended at a dose of 60 mg daily for prevention and treatment, and is a good initial option for younger postmenopausal women 1, 2, 3
Denosumab is recommended at a dose of 60 mg subcutaneously every six months, and is an option for patients with high fracture risk 1, 2, 4

Teriparatide is recommended at a dose of 20 mcg subcutaneously daily for treatment of high fracture risk, and is typically reserved for patients with severe osteoporosis or who have had fractures 1, 2
Calcitonin-salmon is recommended at a dose of 200 IU daily nasal spray or 100 IU subcutaneously/intramuscularly every other day, and is only for women more than five years past menopause 1, 2

Bisphosphonate therapy is typically recommended for 5 years, with a trend toward interrupting therapy after 5-10 years 1, 2, 6
Bone mineral density monitoring during the 5-year pharmacologic treatment period is not recommended 6
Combination therapy is not recommended 1, 2
All patients should receive adequate calcium and vitamin D intake, with recommended daily doses of 1,000-1,200 mg calcium and 600-800 IU vitamin D depending on age 3, 7

For adults ≥40 years with very high fracture risk, consider anabolic agents (teriparatide) over antiresorptives 8, 9
For adults ≥40 years with high fracture risk, oral bisphosphonates are strongly recommended, with denosumab or teriparatide as alternatives 3, 8, 9
For adults ≥40 years with moderate fracture risk, consider oral bisphosphonates, denosumab, or teriparatide based on individual factors 3, 8, 9

Administering alendronate to patients with significant renal impairment (GFR <35 mL/min/1.73m²) is not recommended 10
Discontinuing denosumab without follow-up bisphosphonate therapy can result in rebound bone loss 4, 5
Failing to ensure patients can remain upright for at least 30 minutes after taking oral bisphosphonates can increase the risk of esophageal irritation 1, 2
Not addressing modifiable risk factors (smoking, alcohol intake, inactivity) alongside pharmacological treatment can reduce treatment effectiveness 2, 3
Using calcitonin as first-line therapy is not recommended due to its weaker efficacy data 2, 3